Studies shows safety, efficacy of J&J psoriasis drug

05/15/2008 | Reuters

Two Phase III trials showed that ustekinumab, Johnson & Johnson's psoriasis drug candidate, safely reduced symptoms of the disease for at least a year and was well tolerated by patients. J&J hopes to get the drug approved by September in the U.S. and by early next year in Europe.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Vice President, Idaho Regional Director
Boise, ID